COMMUNIQUÉS West-GlobeNewswire

European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
18/08/2025
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors STAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare [...]
Autonomix Medical, Inc. to Participate in Virtual Investor Webinar Hosted by Ladenburg Thalmann & Co. Inc.
18/08/2025
Live video webcast on Thursday, August 21 st at 1:00 PM ET Register here THE WOODLANDS, TX, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device [...]
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
18/08/2025
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors STAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare [...]
First Patient Enrolled in Merit Medical’s WRAPSODY (WRAP) North America Registry
18/08/2025
The WRAP North America registry is a prospective, multicenter study designed to collect real-world safety and effectiveness data on the WRAPSODY ® Cell-Impermeable Endoprosthesis (CIE). The first WRAP North America [...]
Hapbee Secures Strategic Backing and Commercial Agreement to Enter Multi-Billion Dollar Asian Wellness Market
18/08/2025
Smile Group’s investment unlocks new international pathways for Hapbee’s digital wellness platform VANCOUVER, British Columbia, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Hapbee Technologies Inc. (“Hapbee” or the “Company”) ( [...]
Affidea partners with Skin Analytics to improve access to skin cancer assessment across Europe using AI technology
18/08/2025
THE HAGUE, The Netherlands, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Affidea , a leading pan-European provider of community-based polyclinics, advanced diagnostics, and multi-specialist care, including oncology, has entered a [...]
Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
18/08/2025
Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development of ratutrelvir, a ritonavir-free treatment, compared to PAXLOVID ® Separate single-arm [...]
SRx Health Solutions Signed a Letter of Intent to Acquire the Assets of Royal Uranium
18/08/2025
TAMPA, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (“SRx Health” or the “Company”), a leading global health and wellness company, today announced that is has signed a non- [...]
FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation
18/08/2025
Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for Market Regulation [...]
BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia
18/08/2025
Achieved alignment with the FDA on sNDA package to expand the IGALMI label for the At-Home (Outpatient) setting sNDA submission on track for Q1 2026 NEW HAVEN, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel [...]
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
18/08/2025
Addition of Tuspetinib (TUS) to Venetoclax (VEN) and Azacitidine (AZA) is being developed as safe and mutation agnostic frontline therapy for AML Addition of TUS to VEN+AZA improves response rates; 100% CR/CRh at 80 mg [...]
Theratechnologies annonce le dépôt des documents relatifs à l’assemblée extraordinaire et l’obtention d’une ordonnance provisoire concernant son acquisition par CB Biotechnology, un membre du même groupe que Future Pak
18/08/2025
Les actionnaires pourraient recevoir une prime en espèces considérable et attrayante puisque le prix d’achat de 3,01 $ US, assorti d’un droit conditionnel à la valeur représentant des paiements supplémentaires totaux [...]
Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak
18/08/2025
Shareholders stand to receive a significant and attractive cash premium, as the purchase price of US$3.01, with a contingent value right for potential additional aggregate payments of up to US$1.19 per share, represents [...]
OneMedNet initiates new Subscription Revenue model in partnership with Circle CVI
18/08/2025
MINNEAPOLIS, Aug. 18, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet” or the “Company”), a leader in AI-powered Real-World Data (RWD) announced a long-term strategic partnership with Circle [...]
Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)
18/08/2025
-- Achieved Primary Endpoint with 30mg Dose of RE104 Demonstrating 23.0-Point Reduction from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Score on Day 7, a 5.8-Point Greater Reduction Than Patients [...]
Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases
18/08/2025
REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures RNA sequencing and circulating tumor cell reduction consistent with tumor cell death No dose limiting toxicities were [...]
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
18/08/2025
ENX-CL-05-001 Trial: 3-months topline data - In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including 24% reduction in knee pain and 26% [...]
VIRBAC: Informations sur les conditions de rémunération de Paul Martingell
18/08/2025
Le conseil d’administration de Virbac précise les conditions de rémunération de Paul Matingell en qualité de directeur général. Le conseil d’administration a arrêté, sur recommandation du comité des nominations et des [...]
Virbac:: Paul Martingell's compensation terms
18/08/2025
The board of directors of Virbac specifies Paul Martingell's compensation terms as chief executive officer. The board of directors, acting upon the recommendation of the appointments and compensation committee, has [...]

Pages